<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484675</url>
  </required_header>
  <id_info>
    <org_study_id>milrinone in cardiadc surgery</org_study_id>
    <nct_id>NCT04484675</nct_id>
  </id_info>
  <brief_title>Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension</brief_title>
  <official_title>Comparative Study Between Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator compared difference between inhaled and intravenous milirinone in patiens
      with severe pulmonary hypertension undergoing cardiac surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Milrinone is widely used in cardiac surgery as an inotrope and pulmonary vasodilator agent
      But , intravenous milrinone has been associated with systemic hypotension and increased
      requirement for vasoactive drugs

      The investigator compared difference between inhaled and intravenous milirinone in patiens
      with severe pulmonary hypertension undergoing cardiac surgery
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A computer-generated randomization table divided patients into 2 equal groups randomly allocated patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>change in mean arterial pressure is recorded 10 minutes after milrinone administration after induction (T1), at the end of nebulization (T2), before cardiopulmonary bypass (T3) and after cardiopulmonary bypass(T4)</time_frame>
    <description>The effect of inhaled milrinone on mean arterial pressure is compared with the effect of intravenous milrinone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean pulmonary arterial pressure</measure>
    <time_frame>change in mean pulmonary arterial pressure 10 minutes after milrinone administration</time_frame>
    <description>The effect of inhaled milrinone on mean pulmonary pressure is compared with the effect of intravenous milrinone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic vascular resistance</measure>
    <time_frame>change in systemic vascular resistance 10 minutes after milrinone administration</time_frame>
    <description>The effect of inhaled milrinone on mean pulmonary pressure is compared with the effect of intravenous milrinone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary vascular resistance</measure>
    <time_frame>change in pulmonary vascular resistance 10 minutes after milrinone administration</time_frame>
    <description>The effect of inhaled milrinone on mean pulmonary pressure is compared with the effect of intravenous milrinone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Pulmonary Hypertension Due to Left Heart Disease</condition>
  <arm_group>
    <arm_group_label>Group IH(inhaled milrinone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Iv(Intravenous milrinone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone inhalation</intervention_name>
    <description>After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered</description>
    <arm_group_label>Group IH(inhaled milrinone)</arm_group_label>
    <other_name>primacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone infusion</intervention_name>
    <description>After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered</description>
    <arm_group_label>Group Iv(Intravenous milrinone)</arm_group_label>
    <other_name>primacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with
             estimated mean pulmonary artery pressure =&gt;55 estimated by using preoperative Doppler
             echocardiography

        Exclusion Criteria:

        Patients were excluded if they had surgery without CPB, preoperative hemodynamic
        instability (deﬁned as acute requirement for vasoactive support or mechanical
        device),Patients with severe LV dysfunction (LV ejection fraction of less than 30%
        congenital heart disease, a contraindication to transesophageal echocardiography (TEE),
        emergency surgery or re-do surgeries severe renal or hepatic disease

        , coagulopathy, and thromboembolic disease treated with anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba M EL-Asser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heba M EL-Asser, MD</last_name>
    <phone>01062393152</phone>
    <email>aseelaswad1@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amany S abdelazeem, MD</last_name>
    <phone>01287220016</phone>
    <email>dola.salah2009@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Denault AY, Bussières JS, Arellano R, Finegan B, Gavra P, Haddad F, Nguyen AQ, Varin F, Fortier A, Levesque S, Shi Y, Elmi-Sarabi M, Tardif JC, Perrault LP, Lambert J. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anaesth. 2016 Oct;63(10):1140-53. doi: 10.1007/s12630-016-0709-8. Epub 2016 Jul 28.</citation>
    <PMID>27470232</PMID>
  </reference>
  <reference>
    <citation>Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther. 2009 Apr;26(4):462-8. doi: 10.1007/s12325-009-0019-4. Epub 2009 Apr 16.</citation>
    <PMID>19381522</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Heba Mohamed EL -Asser,MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

